Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) released its earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
Appili Therapeutics Price Performance
Shares of OTCMKTS APLIF opened at $0.01 on Friday. The stock’s 50 day moving average price is $0.01 and its two-hundred day moving average price is $0.01. Appili Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.03. The stock has a market capitalization of $1.20 million, a P/E ratio of -0.23 and a beta of -0.04.
Appili Therapeutics Company Profile
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Featured Stories
- Five stocks we like better than Appili Therapeutics
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
